Enovis (NYSE:ENOV) Upgraded at Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

A number of other analysts have also recently commented on ENOV. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Enovis in a report on Friday, May 22nd. Wells Fargo & Company cut their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. William Blair started coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Finally, Zacks Research downgraded shares of Enovis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, June 30th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Up 0.4%

Shares of ENOV opened at $22.60 on Monday. The business’s fifty day moving average price is $23.23 and its two-hundred day moving average price is $23.84. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1.14 and a beta of 1.39. Enovis has a 52 week low of $19.14 and a 52 week high of $36.82. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. During the same period in the previous year, the business posted $0.81 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts predict that Enovis will post 3.12 earnings per share for the current year.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders have purchased 4,200 shares of company stock worth $92,084 over the last quarter. 2.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ENOV. California State Teachers Retirement System lifted its stake in Enovis by 1.2% in the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company’s stock valued at $1,622,000 after purchasing an additional 621 shares during the last quarter. MGO One Seven LLC increased its position in shares of Enovis by 9.4% during the fourth quarter. MGO One Seven LLC now owns 7,581 shares of the company’s stock worth $202,000 after buying an additional 650 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the period. Empowered Funds LLC increased its position in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after buying an additional 749 shares in the last quarter. Finally, Inscription Capital LLC increased its holdings in shares of Enovis by 9.4% during the fourth quarter. Inscription Capital LLC now owns 11,869 shares of the company’s stock valued at $316,000 after acquiring an additional 1,016 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.